瑞马佐拉姆与妄和认知功能的关联:随机对照试验的系统审查和元分析
Jaime Andres Arias1, Gustavo Roberto Minetto Wegner, Bruno Francisco Minetto Wegner
1From the Universidade Federal da Bahia, Hospital Ana Nery, Salvador, Brazil (JAA), Universidade Federal da Fronteira Sul, Passo Fundo (GRMW), Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (BFMW), Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil (LSS), São Paulo (FJLB) and Universidade de São Paulo, São Paulo, Brazil (RGMF).
European journal of anaesthesiology
|December 19, 2024
概括
与其他镇静剂相比,雷米马佐拉姆不会增加妄想症或认知障碍的风险. 这项研究发现,雷米马佐拉姆与改善短期术后认知功能有关.
科学领域:
- 麻醉学和重症监护医学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 妄想是一种显著的有机精神综合征,与诸如认知衰退,长时间住院和死亡率等不良结果有关.
- 了解麻醉剂对术后认知功能和妄想的影响,对于患者的康复和长期健康至关重要.
- 雷米马佐拉姆是一种较新的超短效二,在麻醉和镇静中具有潜在的优势.
研究的目的:
- 系统地审查和元分析随机对照试验 (RCT),评估雷米扎拉姆与术后认知功能和妄想的关联.
- 为了比较雷米扎拉姆和非二胺催眠药之间的妄想和认知功能变化的发生率.
- 确定可能影响 Delirium 发病率的因素,例如手术类型.
主要方法:
- 进行了RCT的系统审查和元分析.
- 在PubMed,Embase,Cochrane图书馆和Web of Science数据库中进行了搜索,截至2024年4月27日.
- 包括的研究涉及成人患者接受全身麻醉或镇静,比较雷米扎拉姆与其他催眠剂/镇静剂,并评估认知功能或妄想.
主要成果:
- 分析了23个涉及3598名患者的RCT.
- 在雷米马佐拉姆和其他镇静剂之间,没有发现妄发病率的显著差异 (OR=1.2,P=0.3788).
- 雷米马佐拉姆在术后第一和第三天的迷你精神状态检查 (MMSE) 评分没有差异,但在术后第7天显示出优势 (P<0.0001).
结论:
- 与非二胺催眠药相比,雷米马佐拉姆与痴呆症或认知障碍的发病率增加无关.
- 手术的类型被确定为影响妄发病率的重要因素.
- 雷米马佐拉姆的使用与短期术后认知功能的增强有关.
相关概念视频
01:15REM Sleep Behavior Disorder
143
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
143
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
145
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
145
01:19Management of Insomnia
230
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
230
01:23Antidepressant Drugs: MAOIs and Other Agents
194
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
194
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
01:22Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162